Barb Jacobsmeyer: Right. I mean, what I would say is we don’t have a target and mainly because of that balance between the readmission rates and the visits per episode. What I would say is that as we certainly look — a lot of it has to do with the mix of the patients. So, as we grow, again, more of the therapy intensive or rehab intensive type of admissions, those do come usually at higher visits per episode. So, it’s kind of a balance. As we rollout Pulse, that’s obviously the focus is to be able to have more real-time. So, if there’s an ability to lower the visits than what Medalogix initially recommended that Pulse tool is more real-time, so versus the place that still has the care tool out there, they get a onetime snapshot of recommendation.
Pulse keeps it updated and can show that maybe someone needs to go up in visits or maybe they’ve improved and they can go down and visits. So, again, it’s — we don’t really have a target for the field. It’s balancing the appropriate number of visits to manage the high quality.
Joanna Gajuk: If I may just another follow-up on the standalone company cards discussion. So, you’re talking about $9 million to $10 million increase year-over-year. But it feels like maybe it came a little bit better than expected or maybe I wasn’t already following the numbers. But I guess, previously you expect second half of 2022 to be, I guess, $16 million if we say something, but I guess it came at $10 million. So that’s what I was assessing like maybe tracking better. So that’s why like the $9 million to $10 million, is it sort of in line with how you were thinking three months ago about these incremental costs, or if there’s any change in that? Thank you.
Crissy Carlisle: Yeah. So, Joanna, for full year 2022, if I include — remember the first two quarters of the year had the overhead allocation from Encompass Health and in the last two quarters were the standalone costs for the company. Let’s say, for the full year is around $17 million. Those last two quarters, we’re running at about $5 million, which, yeah, is a little bit better than we had first anticipated. Part of that has to do with just the ramp up of staff, which again we think we’re doing a great job in trying to be very cautious as we examine every hire and determine is the timing right and is that the initial plan from the strategic review and the plan to do standalone and ramp up. How are we doing that? How are we assessing that?
Is that still the right path? Asking all those questions. At this time, I still believe that $26 million to $28 million ultimately is the right number. It’s just that it’s — we have ramped up a little bit slower than originally determined.
Operator: The next question is from Larry Solow with CJS Securities. Your line is open.
Barb Jacobsmeyer: Good morning.
Larry Solow: Thanks. Good morning, Crissy and Barb. Thank you for taking the question. Just a couple just to clarify. On the guidance range, relatively wide — especially for the EPS range. I know you mentioned, I guess, the biggest factor is the mix shift and the transition to non-episodic. How — is that — can you just sort of — is that like the $40 million headwind, I guess, that you say from that mix is that sort of the mid-point of guidance and that number is the biggest variable that kind of can swing guidance to a lower or higher end or other things — and other big factors in there?
